Welcome to Ergéa. We enable the potential of healthcare.
Ergéa Group is a leading European cancer care and diagnostic imaging platform. We aim for diversified growth by offering services in four distinct healthcare markets: Managed Equipment Services (MES), Integrated Clinical Services, outpatient clinics and equipment maintenance.
We currently have operations in the UK, Germany and Italy and are gradually entering new markets in Europe.
Ergéa Group by the numbers
employees
Linear Accelerators under management
diagnostic imaging devices under management
Managed Service / Integrated Clinical Solution partnerships
proprietary outpatient practices
Our story
The Ergéa Group has been formed through acquisitions in the healthcare sector, bringing together companies with distinct and complementary business models and company cultures.
With medical doctors establishing the strategic course in our Board of Directors and Supervisory Committee, Ergéa Group is a physician-led organisation that, by default, places patients and healthcare professionals at the heart of the healthcare system. We chose the name Ergéa to symbolise the patient-centric mindset we share across the group.
Like Western medicine itself, the name Ergéa has Greek roots. In Greek, érgo means 'work', and ygeía means 'health'. The blending of these two words as Ergéa can be roughly translated to "working for health". The translation 'working for health' captures our ambition to bring better healthcare to the place where it has the most significant impact – at the patient interface. This is where the healthcare system meets the patient to make a difference in each individual's life.
Our journey
Established in 2020, we’re on a journey to enable better medical outcomes and improved patient experiences across Europe. Here are the key milestones that got us to where we are today.
DWS, one of the largest European infrastructure investors, establishes a company and a long-term plan to acquire and develop healthcare companies that exhibit strong infrastructure characteristics.
The headquarters of the newly founded company are established in Luxembourg, a country with a robust environment conducive to business growth, a strategic location in the middle of Europe and a multicultural and highly skilled workforce.
The first acquisitions, Medipass S.p.A in Italy and its UK affiliate Medipass Healthcare Ltd, form a strong foundation for building a pan-European healthcare infrastructure platform.
DWS acquires RadioOnkologieNetzwerk GmbH, the largest provider in the fragmented radiotherapy clinics market, to gain access to the German market.
With the acquisition of Althea UK and Ireland Ltd, the platform’s presence in the UK is expanded significantly, enabling the group to offer a market-leading service in the ISO MES1 segment. Althea UK and Ireland brings extensive operational experience and a breadth of relationships with the NHS and private health sector.
The expanding group is brought under one name, with local variations.
- Our UK affiliates, Medipass Healthcare Ltd and Althea UK and Ireland Ltd, are merged and fully rebranded as Ergéa UK and Ireland Ltd.
- Our Italian affiliate, Medipass S.p.A, is co-branded under Ergéa group.
- Our German affiliate, RadioOnkologieNetzwerk, is cobranded under Ergéa group.
Our locations
Medipass SpA
Via Ilio Barontini, 20
40138 Bologna
Italy
RadioOnkologieNetzwerk
Ulmer Str. 68
73431 Aalen
Germany
Ergea UK and Ireland Ltd
Units 4-6, Ely Road
Theale Commercial Estate
Theale, Reading
RG7 4BQ
France
Board of Directors,
Ergea Group S.à r.l.
Board of Directors,
Ergea Group S.à r.l.
Board of Directors,
Ergea Group S.à r.l.
Board of Directors,
Ergea Group S.à r.l.
Dr. Guglielmo Brayda di Soleto is a founding partner of our Italian and UK affiliate, Medipass, and Co-Chairperson of the Ergéa group’s Board of Directors.
He is a trained neurologist and neuroradiologist with numerous scientific publications in MRI neurology and extensive experience in business management, clinical services and Private-Public Partnerships (PPPs).
In his current role, Dr. Brayda di Soleto helps shape the strategic direction of the group, leads Ergéa Group’s Scientific Medical Committee, and supports the group's expansion into new geographical markets.
Board of Directors,
Ergea Group S.à r.l.
A founding partner of RadioOnkologieNetzwerk and its first practice in Baden-Württemberg, Dr. Sandra Röddiger is Co-Chairperson of the Ergéa group’s Board of Directors. As a trained medical doctor with over 20 years of experience as a radiation oncologist, she brings clinical perspective and understanding of day-to-day operations to the organization's decision-making processes, resulting in a more patient-centered approach as well as focus on employee wellbeing and retention. Having worked over 10 years as an entrepreneur, she has also considerable experience in business management. In her current role, Dr. Röddiger helps shaping the strategic direction of the group, as well as further enhancing the medical and operational excellence across the whole group. Dr. Röddiger does clinical work regularly to keep her skills and knowledge current.
Board of Directors,
Ergea Group S.à r.l.
Dr Ralf Kurek is a co-founder of RadioOnkologieNetzwerk and its first clinic in Baden-Württemberg, and the Co-Chairperson of the Ergéa Group’s Board of Directors. With over 20 years of experience as radiation oncologist and over 10 years as an entrepreneur, Dr. Kurek has considerable knowledge of both clinical operations and business management. In his current role, he helps shaping the strategic direction of the group, as well as further enhancing the medical and operational excellence across the whole group. To keep his clinical skills and knowledge current, he continues to work regularly as a radiation oncologist.
Our region executives
Our Executive Committee focuses on growing business and continuously meeting the needs of our future and current customers in a rapidly changing environment.
Ergéa Group S.à r.l.
Ergea Deutschland GmbH
Ergea UK and Ireland Ltd
Ergéa Group S.à r.l.
Ergea Deutschland GmbH
With a distinctive blend of expertise and experience encompassing both the business and clinical domains, Dr. Michael Thorwarth leads the implementation of Ergéa Group's business expansion strategy, while also serving as CEO of Ergéa Deutschland.
Trained as a medical doctor specialised in maxillofacial surgery, he brings a clinical perspective and a patient-centered approach to his role.
Having transitioned to business management, Dr. Thorwarth has previously served as a Partner and Managing Director at Boston Consulting Group. He has also successfully built a group of dental care centers in Germany, showcasing his proficiency in both healthcare and business leadership.
As the CEO of Medipass S.p.A, Michele Corti draws on his extensive experience in both consulting and business development to drive the success of the organisation. He defines the affiliate’s strategic direction, oversees acquisition initiatives and navigates complex negotiations to drive business expansion in Italy with a focus on outpatient centres and clinical services.
Ergea UK and Ireland Ltd
As the CEO of Ergéa in UK and Ireland, David Rolfe leads the organization with a spirit of partnership and innovation. He has over 20 years of experience leading companies that provide Medical Equipment Services (MES) for the NHS and a proven track of record in achieving sustainable business growth. He was one of the founders of two of the key businesses that are now part of Ergéa UK: Asteral, the first independent managed service business in the UK, and Medipass Healthcare, an MES company operating in radiology and radiotherapy.
The majority owner of Ergéa Group is DWS, one of the world’s leading asset and infrastructure managers, on behalf of one of its European infrastructure funds.
The co-founders of our German affiliate, Dr Sandra Röddiger and Dr Ralf Kurek, are the largest private shareholders of the company and together with representatives from DWS Infrastructure and Dr. Guglielmo Brayda di Soleto form the Board of Directors, which defines the strategic direction of the group. Also several members of our operational management have vested personally in the success of Ergéa.
Strong support from our shareholders allows us to focus on long-term growth and pursue new opportunities whilst providing a return on stakeholder investment.